CMS Natrecor NCD
Medicare contractors may opt to cover J&J/Scios' Natrecor for some off-label uses despite a March 2 CMS national coverage decision against using nesiritide for chronic heart failure. The decision "does not change contractor discretion to cover other off-label uses of nesiritide" or affect coverage for the labeled indication of acutely decompensated heart failure, CMS said. The agency had expressed concern about the drug's potential for increased mortality rates and renal dysfunction. The NCD review found inconsistent data on use of Natrecor for chronic heart failure (1"The Pink Sheet" Dec. 12, 2005, p. 12)...
You may also be interested in...
The Centers for Medicare & Medicaid Services is proposing to restrict Medicare coverage of Johnson & Johnson/Scios' Natrecor to its labeled indication for acutely decompensated heart failure, rather than provide wider coverage for the drug under a "coverage with evidence development" program
Similarities to AstraZeneca blood clots are clear, but more research needed before any ‘class effect’ conclusions can be drawn.
Hikma has restarted launch activities for its generic version of GSK’s Advair respiratory blockbuster in the US, after the FDA gave the go-ahead following approval of an ANDA amendment.